相关实验视频

Updated: Jun 28, 2025

Structural Biology and Analytical Chemistry Approaches for Characterizing C-Glycoside Metabolic Enzymes in Human Gut Microbiota

Structural Biology and Analytical Chemistry Approaches for Characterizing C-Glycoside Metabolic Enzymes in Human Gut Microbiota

Published on: May 23, 2025

建议的非竞争性抑制的分子机制使用α-葡萄糖酶酶和作为抗糖尿病药物的曼戈斯化合物之间的分子动力学模拟

Ahmad Fariz Maulana¹, Iman Permana Maksum², Sriwidodo Sriwidodo³

¹Department of Chemistry, Faculty of Mathematics and Natural Sciences, Padjadjaran University, Jatinangor, Sumedang, 45363, Indonesia.

Journal of molecular modeling

|April 18, 2024

概括

这项研究探讨了设计α-葡萄糖酶抑制剂的分子机制. 与acarbose相比,3,6,7-trimethyl-ester-γ-mangostin在中显示出更好的抗糖尿病药物潜力.

科学领域:

生物化学生物化学
计算化学计算化学
药理学药理学是指药理学的学科.

背景情况:

了解分子机制对于开发新型抗糖尿病药物至关重要.
阿尔法-葡萄糖酶抑制剂是治疗糖尿病的关键治疗策略.
这项研究侧重于潜在的α-葡萄糖酶抑制剂的分子相互作用.

研究的目的:

为了研究底层的α-葡萄糖酶抑制的分子机制.
用计算方法识别用于抗糖尿病药物设计的强效化合物.
为了比较一种新型化合物的抑制机制与已知的药物 (acarbose).

主要方法:

从RCSB中检索蛋白质结构并使用ChemDraw Professional生成配体.
使用Autodock Vina进行分子对接,并使用Amber软件进行分子动力学模拟.
自由能量计算 (MM/GBSA),静电,范德瓦尔斯和键相互作用的分析.

主要成果:

四种化合物,包括γ-曼戈斯衍生物,表现出显著的结合亲和力.
与阿卡尔相比,3,6,7-三甲基-γ-曼戈斯显示出更高的自由能量.
3,6,7-trimethyl-ester-γ-mangostin通过非竞争性抑制作用,而阿卡尔通过竞争性抑制作用.

结论:

3,6,7-trimethyl-ester-γ-mangostin是一种γ-mangostin衍生物,在中显示出有前途的抗糖尿病活性.
像分子对接和动力学这样的计算方法对药物发现有效.
独特的抑制机制为设计更有效的抗糖尿病药物提供了洞察力.

关键词:

这是一种抗糖尿病药物.糖尿病糖尿病糖尿病在状的中.分子对接是分子对接.分子动力学模拟模型

更多相关视频

Modeling an Enzyme Active Site using Molecular Visualization Freeware

Modeling an Enzyme Active Site using Molecular Visualization Freeware

Published on: December 25, 2021

Author Spotlight: Exploring Cellular Processes by Modeling Ligands in Cryo-EM Maps

Author Spotlight: Exploring Cellular Processes by Modeling Ligands in Cryo-EM Maps

Published on: July 19, 2024

相关概念视频

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...

Enzyme Inhibition

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.

Indirect-Acting Cholinergic Agonists: Mechanism of Action

Indirect-Acting Cholinergic Agonists: Mechanism of Action

Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Enzymes

Enzymes

Inside living organisms, enzymes act as catalysts for many biochemical reactions involved in cellular metabolism. The role of enzymes is to reduce the activation energies of biochemical reactions by forming complexes with its substrates. The lowering of activation energies favor an increase in the rates of biochemical reactions.
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...